Preclinical and clinical evidence continues to point towards a therapeutic role for dual ErbB3 and EGFR targeting in HPV-negative HNSCC; however, the successful development of both tolerable and effective drugs or combinations has been elusive. Here, ERBB3 is linked to head and neck squamous cell carcinoma.